Graftcept500 mg

Graftcept is indicated for the following uses:

Established / FDA-approved uses

• Prophylaxis of organ rejection in patients receiving allogeneic kidney transplants, in combination with cyclosporine (or tacrolimus) and corticosteroids.
• Prophylaxis of organ rejection in patients receiving allogeneic heart transplants, in combination with other immunosuppressants.
• Prophylaxis of organ rejection in patients receiving allogeneic liver transplants, in combination with other immunosuppressants.

Guideline-supported / commonly used off-label uses

• Induction and maintenance therapy of lupus nephritis (Class III-V), as part of a combination immunosuppressive regimen, based on treatment guidelines.
• Other autoimmune and inflammatory conditions (e.g., certain forms of vasculitis, autoimmune hepatitis, some dermatologic autoimmune disorders) where used off-label under specialist supervision.

Graftcept is always used in combination with other immunosuppressive agents and must be prescribed and monitored by a physician experienced in transplant medicine or the relevant autoimmune condition.

Each tablet/capsule of Mycophenolate Mofetil generally contains 250 mg or 500 mg of mycophenolate mofetil as the active ingredient. Oral suspension and intravenous formulations are also available in some markets. Strength and dosage form available may vary by manufacturer; refer to the specific product packaging for exact composition.

Graftcept is a potent immunosuppressive agent derived from mycophenolic acid. It is a prodrug that is rapidly hydrolyzed after absorption to its active metabolite, mycophenolic acid (MPA), which selectively inhibits an enzyme essential for lymphocyte proliferation. Graftcept is used primarily to prevent rejection of transplanted organs and, in certain autoimmune conditions, to suppress an overactive immune response. It carries boxed warnings for increased risk of pregnancy loss, congenital malformations, infections, and malignancy, and must only be used under close physician supervision.

Graftcept belongs to the therapeutic class of immunosuppressive agents, specifically the subclass of selective inosine monophosphate dehydrogenase (IMPDH) inhibitors. It is classified as an antiproliferative immunosuppressant used in solid organ transplantation and select autoimmune diseases.

Mycophenolate Mofetil is rapidly hydrolyzed to mycophenolic acid (MPA), its pharmacologically active form. MPA is a potent, selective, reversible, and uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical in the de novo pathway of guanosine nucleotide synthesis. T- and B-lymphocytes are highly dependent on this de novo pathway for proliferation, whereas most other cell types can use a salvage pathway. By blocking this pathway, Mycophenolate Mofetil selectively inhibits lymphocyte proliferation, antibody formation, and cellular adhesion molecule generation, thereby suppressing cell-mediated and humoral immune responses that drive organ rejection and certain autoimmune processes.

Pharmacokinetics: Following oral administration, Mycophenolate Mofetil is almost completely absorbed and rapidly converted to MPA. MPA is highly protein-bound (~97%) and is metabolized in the liver to an inactive glucuronide metabolite (MPAG), which undergoes enterohepatic recirculation. Elimination is primarily renal, mostly as MPAG.

Graftcept is administered orally (tablet, capsule, or oral suspension) or, in hospital settings, by intravenous infusion over at least 2 hours for patients unable to take oral medication. Oral doses should be taken consistently with respect to meals, swallowed whole without crushing or chewing, and evenly spaced approximately 12 hours apart. Caregivers who are pregnant or may become pregnant should avoid direct contact with broken or crushed tablets/capsules or the contents of the oral suspension.

Graftcept has several clinically significant drug interactions:

• Antacids (magnesium/aluminum hydroxide): Reduce absorption of Graftcept; separate dosing by at least 2 hours if concurrent use is necessary.
• Proton pump inhibitors and H2-receptor antagonists: May reduce exposure to mycophenolic acid by altering gastric pH; clinical significance should be monitored.
• Cholestyramine and other bile-acid sequestrants: Reduce mycophenolic acid exposure through interruption of enterohepatic recirculation; avoid concurrent use.
• Antimicrobials that alter gut flora (e.g., some oral antibiotics): May reduce mycophenolic acid levels by disrupting enterohepatic recirculation.
• Acyclovir, ganciclovir, valganciclovir: Both compete for renal tubular secretion; concurrent use may raise blood levels of both drugs, requiring monitoring especially in renal impairment.
• Live attenuated vaccines: Immune response may be reduced and vaccine-strain infection may occur; live vaccines should generally be avoided during treatment with Graftcept.
• Hormonal contraceptives: Graftcept does not appear to reduce combined oral contraceptive efficacy significantly, but reliable contraception (often including a barrier method) is still strongly recommended given teratogenicity risk (see Pregnancy and Lactation).
• Other immunosuppressants (cyclosporine, tacrolimus, azathioprine): Used in combination by design, but increase overall immunosuppression and infection/malignancy risk; requires close monitoring.

Common and serious side effects of Graftcept include:

Very common

• Diarrhea and other gastrointestinal disturbances (nausea, vomiting, abdominal pain) - can be severe and dose-limiting.
• Leukopenia and other blood count abnormalities.
• Increased susceptibility to bacterial, viral (including CMV, herpes), fungal, and opportunistic infections.

Common

• Headache, tremor, insomnia.
• Hypertension, peripheral edema.
• Elevated liver enzymes.

Serious (less common but important)

• Severe neutropenia, anemia, thrombocytopenia (requires regular blood monitoring).
• Increased risk of lymphoma and other malignancies (particularly skin cancers) due to chronic immunosuppression.
• Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection.
• Gastrointestinal bleeding or perforation (rare).
• Pure red cell aplasia (rare).

Patients should promptly report fever, unusual bruising/bleeding, persistent diarrhea, or signs of infection to their physician.

Pregnancy

Graftcept is associated with an increased risk of first-trimester pregnancy loss and congenital malformations (including malformations of the ears, face, limbs, heart, esophagus, and kidneys) when used during pregnancy. Graftcept is contraindicated in pregnancy except in specific circumstances where a specialist determines the benefit clearly outweighs the risk and no suitable alternative exists. Females of reproductive potential must have a negative pregnancy test before starting therapy and must use effective contraception (two reliable methods, or one highly effective method, generally including a barrier method) before, during, and for 6 weeks after stopping Graftcept. Male patients with partners of reproductive potential are generally advised to use condoms during treatment and for a defined period after stopping therapy. Consult a physician immediately if pregnancy is suspected or confirmed while taking Graftcept.

Lactation

Graftcept is excreted in breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Graftcept. Use only if clearly needed and after discussion with a physician about the risks and benefits.

Graftcept carries important warnings requiring close medical supervision:

• Malignancies: Chronic immunosuppression with Graftcept increases the risk of developing lymphomas and other malignancies, particularly of the skin. Patients should limit sun exposure and use protective clothing/sunscreen.
• Serious infections: Increased susceptibility to bacterial, fungal, viral, and protozoal infections, including opportunistic infections and reactivation of latent viral infections (e.g., hepatitis B/C, CMV, BK virus); regular monitoring is required.
• Blood dyscrasias: Regular complete blood counts (weekly during the first month, twice monthly for the second and third months, then monthly through the first year) are recommended to detect neutropenia, anemia, or thrombocytopenia.
• Gastrointestinal toxicity: Diarrhea and other GI symptoms can be severe; dose reduction or temporary interruption may be required. GI bleeding and, rarely, perforation have occurred, particularly in patients with pre-existing GI disease.
• Live vaccines: Avoid administration of live attenuated vaccines during treatment; ensure vaccinations are updated prior to starting therapy where possible.
• Embryofetal toxicity: See Pregnancy and Lactation - effective contraception is mandatory for patients of reproductive potential.
• Use only under specialist supervision: Graftcept should be prescribed only by, or in consultation with, physicians experienced in transplant management or treatment of the relevant autoimmune condition, with appropriate laboratory monitoring facilities available.

Overdose of Graftcept may present with increased hematologic toxicity (leukopenia, neutropenia) and gastrointestinal symptoms (nausea, vomiting, diarrhea). There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment is supportive, with monitoring of blood counts and general medical support as needed. Hemodialysis is generally not effective at removing clinically significant amounts of the active metabolite at usual doses.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Oral suspension, once reconstituted, should be stored as directed on the label (refer to product packaging for specific reconstituted-suspension storage duration and temperature).

Renal impairment

In patients with severe chronic renal impairment outside the immediate post-transplant period, avoid doses above 1 g twice daily and monitor closely; no adjustment is generally needed for mild-to-moderate impairment.

Hepatic impairment

No specific dose adjustment is established, but clinical monitoring is recommended in patients with significant hepatic disease.

Elderly

Graftcept may be associated with a higher risk of certain adverse effects (e.g., infections, gastrointestinal bleeding) in elderly patients compared with younger patients; use with appropriate caution and monitoring.

Pediatric

See Pediatric Uses section below.

Duration of treatment with Graftcept depends on the indication. For transplant rejection prophylaxis, therapy is generally continued long-term (often lifelong) as part of maintenance immunosuppression, under continuous physician supervision. For lupus nephritis, treatment duration (induction versus maintenance phase) is individualized by the treating specialist based on disease response. Patients must not stop or alter therapy without consulting their physician, given the risk of organ rejection or disease flare.

Mycophenolate Mofetil is classified as an immunosuppressive agent, specifically an inosine monophosphate dehydrogenase (IMPDH) inhibitor / antiproliferative immunosuppressant.

Mycophenolate Mofetil is hydrolyzed to its active form, mycophenolic acid (MPA), which selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo purine (guanosine nucleotide) synthesis pathway. Because activated T- and B-lymphocytes depend heavily on this de novo pathway (unlike most other cell types, which can use an alternate salvage pathway), Mycophenolate Mofetil selectively suppresses lymphocyte proliferation and antibody production, reducing the immune-mediated rejection of transplanted organs and dampening autoimmune inflammatory processes.

Graftcept is approved for prophylaxis of renal transplant rejection in pediatric patients 3 months of age and older, dosed on a body-surface-area basis (approximately 600 mg/m² orally twice daily, maximum 2 g/day), using the oral suspension formulation for accurate weight-based dosing in younger or smaller children where appropriate. Safety and efficacy for cardiac and hepatic transplant rejection prophylaxis in pediatric patients have not been definitively established in the same manner as for renal transplant, and use in these settings should be guided by a pediatric transplant specialist. Use in lupus nephritis or other autoimmune indications in children is off-label and should only be undertaken by a specialist experienced in pediatric autoimmune disease management, with close monitoring for growth, infection, and blood count abnormalities.